Analysts rate Ginkgo Bioworks Holdings (DNA:NYE) with a Buy rating and a $7 target

STA Research
by: STA Research
DNA stock

Analysts rate Ginkgo Bioworks Holdings (DNA:NYE) with a consensus Buy rating and an average DNA stock price target of $7.73 per share over the next 12 months.

Based on the Ginkgo Bioworks Holdings stock forecast from 4 analysts, the average analyst DNA stock price target is USD 7.73 over the next 12 months. Ginkgo Bioworks Holdings’s average analyst rating is Buy. Stock Target Advisor’s own stock analysis of Ginkgo Bioworks stock is Bearish, which is based on 1 positive signal and 4 negative signals. At the last closing, Ginkgo Bioworks stock price was USD 3.17Ginkgo Bioworks stock price has changed by +0.66% over the past week, -0.46% over the past month and +0.00% over the last year.

About Ginkgo Bioworks Holdings (DNA:NYE):

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

 

Most Recent Analysts ratings for DNA’s stock:

What we like:

High market capitalization:

DNA stock is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

 

What we don’t like:

Overpriced compared to book value:

Ginkgo Bioworks stock price is trading high compared to its peers median on a price to book value basis.

Negative cashflow:

Ginkgo stock had negative total cash flow in the most recent four quarters.

Negative free cash flow:

Ginkgo stock had negative total free cash flow in the most recent four quarters.

Low Earnings Growth:

Ginkgo Bioworks stock has shown below median earnings growth in the previous 5 years compared to its sector

Disclaimer

Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.